Connecticut Biotech Veradermics Secures $150M for Phase 3 Trials of Oral Rogaine
Veradermics, a Connecticut-based biotechnology company, has raised $150 million to fund Phase 3 clinical trials of its oral formulation of Rogaine (minoxidil)13456.
This funding round is one of the major investments in the hair loss biotech sector in 20256.
The company is advancing the development of an oral version of Rogaine, traditionally used as a topical hair loss treatment13.
The Phase 3 trials will evaluate the efficacy and safety of the oral therapy in larger patient populations, as required for potential regulatory approval14.
The announcement was made on October 16, 2025145.
Sources:
1. https://endpoints1707.rssing.com/chan-80440327/index-page240.html
3. https://endpoints1707.rssing.com/chan-80440327/article4798.html?nocache=0
5. https://bcbn.org/boston-cambridge-biotech-news/2025/10/16/bxps-waltham-building-lands-tenant-with-newly-approved-drug/